Please enable JavaScript to continue using this application.

Compare $ALXO vs $CUE | Chartloom

Compare

$ALXO vs $CUE

ALX Oncology Holdings Inc · Cue Biopharma Inc

ALXO

ALX Oncology Holdings Inc

CUE

Cue Biopharma Inc

Compare $ALXO vs $CUE

Comparing ALX Oncology Holdings Inc and Cue Biopharma Inc

ALXOALX Oncology Holdings Inc

CUECue Biopharma Inc

ALXOALX Oncology Holdings Inc

Market cap

$168M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

8.7%

52W performance

-36.5%

FCF yield

-42.2%

CUECue Biopharma Inc

Market cap

$112M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

354.4%

YTD performance

173.6%

52W performance

7.5%

FCF yield

-44.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALXO

CUE

Detailed metrics comparison

ALXO

ALX Oncology Holdings Inc

CUE

Cue Biopharma Inc

Market Cap

ALXO$168M

CUE$112M

Enterprise Value

ALXO$156M

CUE$95M

Price

ALXO$1.25

CUE$27.66

P/E Ratio

ALXON/A

CUEN/A

P/S Ratio

ALXO46.09x

CUE2.98x

EV/Sales

ALXO0.00x

CUE2.51x

EV/EBITDA

ALXO0.00x

CUE0.00x

P/B Ratio

ALXO1.24x

CUE80.41x

P/FCF Ratio

ALXON/A

CUEN/A

EV/FCF

ALXO-2.20x

CUE-1.89x

PEG Ratio

ALXON/A

CUEN/A

Forward P/E (NTM)

ALXON/A

CUEN/A

Forward P/S (NTM)

ALXON/A

CUEN/A

Revenue (TTM)

ALXO$0

CUE$38M

Revenue Growth (YoY)

ALXON/A

CUE354.4%

Forward Rev Growth

ALXO357.6%

CUE-38.2%

Gross Margin (TTM)

ALXO9.0%

CUE0.0%

Operating Margin (TTM)

ALXO0.0%

CUE0.0%

EBITDA Margin (TTM)

ALXO0.0%

CUE-258.4%

Net Margin (TTM)

ALXO0.0%

CUE-435.8%

FCF Margin (TTM)

ALXON/A

CUE-133.2%

Net Income (TTM)

ALXO$-81M

CUE$-164M

FCF (TTM)

ALXO$-71M

CUE$-50M

EPS (TTM)

ALXO-$0.60

CUE-$25.88

ROE (TTM)

ALXO-9030.0%

CUE-103219.0%

ROA (TTM)

ALXO-6728.0%

CUE-48467.0%

ROIC (TTM)

ALXO-8046.0%

CUE-100612.0%

Cash

ALXO$23M

CUE$17M

Debt

ALXO$11M

CUE$0

Net Cash/Debt

ALXO$12M

CUE$17M

Current Ratio (TTM)

ALXO9.71x

CUE1.25x

Quick Ratio (TTM)

ALXO9.44x

CUE1.16x

Debt/Equity (TTM)

ALXO0.08x

CUE0.00x

Debt/Assets (TTM)

ALXO0.0%

CUE0.0%

Interest Coverage (TTM)

ALXON/A

CUEN/A

Net Debt/EBITDA (TTM)

ALXO0.00x

CUE0.00x

Beta

ALXO0.55

CUE2.84

52W Performance

ALXO-36.5%

CUE7.5%

YTD Performance

ALXO8.7%

CUE173.6%

% from 52W High

ALXO-53.0%

CUE-39.2%

% from 52W Low

ALXO19.0%

CUE456.4%

Asset Turnover (TTM)

ALXO0.00x

CUE1.11x

FCF Yield (TTM)

ALXO-42.2%

CUE-44.8%

Earnings Yield (TTM)

ALXO-48.1%

CUE-146.5%

Dividend Yield (TTM)

ALXON/A

CUEN/A

Rule of 40

ALXO0.0

CUE221.1

EV/GP/RG

ALXON/A

CUEN/A

Ticker research

View ALXO research View CUE research

Metric	ALXO ALX Oncology Holdings Inc	CUE Cue Biopharma Inc
Market & Valuation
Market Cap	$168M	$112M
Enterprise Value	$156M	$95M
Price	$1.25	$27.66
P/E Ratio	N/A	N/A
P/S Ratio	46.09x	2.98x
EV/Sales	0.00x	2.51x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.24x	80.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.20x	-1.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$38M
Revenue Growth (YoY)	N/A	354.4%
Forward Rev Growth	357.6%	-38.2%
Profitability
Gross Margin (TTM)	9.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-258.4%
Net Margin (TTM)	0.0%	-435.8%
FCF Margin (TTM)	N/A	-133.2%
Net Income (TTM)	$-81M	$-164M
FCF (TTM)	$-71M	$-50M
EPS (TTM)	-$0.60	-$25.88
ROE (TTM)	-9030.0%	-103219.0%
ROA (TTM)	-6728.0%	-48467.0%
ROIC (TTM)	-8046.0%	-100612.0%
Financial Health
Cash	$23M	$17M
Debt	$11M	$0
Net Cash/Debt	$12M	$17M
Current Ratio (TTM)	9.71x	1.25x
Quick Ratio (TTM)	9.44x	1.16x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.55	2.84
52W Performance	-36.5%	7.5%
YTD Performance	8.7%	173.6%
% from 52W High	-53.0%	-39.2%
% from 52W Low	19.0%	456.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.11x
FCF Yield (TTM)	-42.2%	-44.8%
Earnings Yield (TTM)	-48.1%	-146.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	221.1
EV/GP/RG	N/A	N/A
Ticker research	View ALXO research	View CUE research

Valuation

P/S Ratio

CUE

2.98x

ALXO

46.09x

EV/FCF

ALXO

-2.20x

CUE

-1.89x

Growth & revenue

Revenue Growth TTM

CUE

354.4%

Forward Revenue Growth

ALXO

357.6%

CUE

-38.2%

Profitability & performance

Gross Margin

ALXO

9.0%

CUE

0.0%

ROE

ALXO

-9030.0%

CUE

-103219.0%

FCF Yield %

ALXO

-42.2%

CUE

-44.8%

52-Week Performance

CUE

7.5%

ALXO

-36.5%

Detailed metrics comparison

ALXO

ALX Oncology Holdings Inc

CUE

Cue Biopharma Inc

Market Cap

ALXO$168M

CUE$112M

Enterprise Value

ALXO$156M

CUE$95M

Price

ALXO$1.25

CUE$27.66

P/E Ratio

ALXON/A

CUEN/A

P/S Ratio

ALXO46.09x

CUE2.98x

EV/Sales

ALXO0.00x

CUE2.51x

EV/EBITDA

ALXO0.00x

CUE0.00x

P/B Ratio

ALXO1.24x

CUE80.41x

P/FCF Ratio

ALXON/A

CUEN/A

EV/FCF

ALXO-2.20x

CUE-1.89x

PEG Ratio

ALXON/A

CUEN/A

Forward P/E (NTM)

ALXON/A

CUEN/A

Forward P/S (NTM)

ALXON/A

CUEN/A

Revenue (TTM)

ALXO$0

CUE$38M

Revenue Growth (YoY)

ALXON/A

CUE354.4%

Forward Rev Growth

ALXO357.6%

CUE-38.2%

Gross Margin (TTM)

ALXO9.0%

CUE0.0%

Operating Margin (TTM)

ALXO0.0%

CUE0.0%

EBITDA Margin (TTM)

ALXO0.0%

CUE-258.4%

Net Margin (TTM)

ALXO0.0%

CUE-435.8%

FCF Margin (TTM)

ALXON/A

CUE-133.2%

Net Income (TTM)

ALXO$-81M

CUE$-164M

FCF (TTM)

ALXO$-71M

CUE$-50M

EPS (TTM)

ALXO-$0.60

CUE-$25.88

ROE (TTM)

ALXO-9030.0%

CUE-103219.0%

ROA (TTM)

ALXO-6728.0%

CUE-48467.0%

ROIC (TTM)

ALXO-8046.0%

CUE-100612.0%

Cash

ALXO$23M

CUE$17M

Debt

ALXO$11M

CUE$0

Net Cash/Debt

ALXO$12M

CUE$17M

Current Ratio (TTM)

ALXO9.71x

CUE1.25x

Quick Ratio (TTM)

ALXO9.44x

CUE1.16x

Debt/Equity (TTM)

ALXO0.08x

CUE0.00x

Debt/Assets (TTM)

ALXO0.0%

CUE0.0%

Interest Coverage (TTM)

ALXON/A

CUEN/A

Net Debt/EBITDA (TTM)

ALXO0.00x

CUE0.00x

Beta

ALXO0.55

CUE2.84

52W Performance

ALXO-36.5%

CUE7.5%

YTD Performance

ALXO8.7%

CUE173.6%

% from 52W High

ALXO-53.0%

CUE-39.2%

% from 52W Low

ALXO19.0%

CUE456.4%

Asset Turnover (TTM)

ALXO0.00x

CUE1.11x

FCF Yield (TTM)

ALXO-42.2%

CUE-44.8%

Earnings Yield (TTM)

ALXO-48.1%

CUE-146.5%

Dividend Yield (TTM)

ALXON/A

CUEN/A

Rule of 40

ALXO0.0

CUE221.1

EV/GP/RG

ALXON/A

CUEN/A

Ticker research

View ALXO research View CUE research

Metric	ALXO ALX Oncology Holdings Inc	CUE Cue Biopharma Inc
Market & Valuation
Market Cap	$168M	$112M
Enterprise Value	$156M	$95M
Price	$1.25	$27.66
P/E Ratio	N/A	N/A
P/S Ratio	46.09x	2.98x
EV/Sales	0.00x	2.51x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.24x	80.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.20x	-1.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$38M
Revenue Growth (YoY)	N/A	354.4%
Forward Rev Growth	357.6%	-38.2%
Profitability
Gross Margin (TTM)	9.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-258.4%
Net Margin (TTM)	0.0%	-435.8%
FCF Margin (TTM)	N/A	-133.2%
Net Income (TTM)	$-81M	$-164M
FCF (TTM)	$-71M	$-50M
EPS (TTM)	-$0.60	-$25.88
ROE (TTM)	-9030.0%	-103219.0%
ROA (TTM)	-6728.0%	-48467.0%
ROIC (TTM)	-8046.0%	-100612.0%
Financial Health
Cash	$23M	$17M
Debt	$11M	$0
Net Cash/Debt	$12M	$17M
Current Ratio (TTM)	9.71x	1.25x
Quick Ratio (TTM)	9.44x	1.16x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.55	2.84
52W Performance	-36.5%	7.5%
YTD Performance	8.7%	173.6%
% from 52W High	-53.0%	-39.2%
% from 52W Low	19.0%	456.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.11x
FCF Yield (TTM)	-42.2%	-44.8%
Earnings Yield (TTM)	-48.1%	-146.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	221.1
EV/GP/RG	N/A	N/A
Ticker research	View ALXO research	View CUE research